ArticleMolecular psychiatry2023
Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk.
Article in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Investigating event-related potential (ERP) deviations in clinical high-risk populations for psychosis: a systematic review and meta-analysis.BMC psychiatry · 2026Pooled it
- Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis.JAMA psychiatry · 2024Pooled it
- Network-Based Spreading of Gray Matter Changes Across Different Stages of Psychosis.JAMA psychiatry · 2023Trial
- Protective Factors Predict Resilient Outcomes in Clinical High-Risk Youth with the Highest Individualized Psychosis Risk Scores.Schizophrenia bulletin · 2026Article
- Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.Molecular psychiatry · 2026Article
- Family-Level Brain Pattern Similarities and Their Clinical Significance in Young Offspring of Individuals With Psychotic Disorders.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Article
- The Effects of Antipsychotics on Two Month Cortical Thickness and Two Year Clinical Outcomes Among Populations at Clinical High Risk for Psychosis.Schizophrenia bulletin · 2026Article
- Widespread synaptic density loss in schizophrenia follows molecular and network architecture.Molecular psychiatry · 2026Article
- Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences.Molecular psychiatry · 2026Article
- Distinct brain volume abnormalities in clinical high-risk individuals: pre- and post-antipsychotic treatment.Psychological medicine · 2026Article
- Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.Molecular psychiatry · 2026Article
- Vertexwise Cortical Deviation Mapping (VCDM): A precision approach to cortical thickness assessment in non-affective psychosis.Brain imaging and behavior · 2026Article
- Resting-state connectivity and tobacco smoking in clinical high-risk for psychosis (NAPLS-3).General psychiatry · 2026Article
- Interaction between Neighborhood Exposome and Genetic Risk in Child Persistent Distressing Psychotic-like Experiences.Nature. Mental health · 2026Article
- Synergistic pathways to psychosis: understanding developmental risk and resilience factors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Repurposing medications to prevent psychosis.Npj mental health research · 2025Review
- Tobacco Smoking and Gray Matter Volume in Individuals at Clinical High Risk for Psychosis: A Longitudinal Magnetic Resonance Imaging Study.Biological psychiatry global open science · 2025Article
- Cognitive and Global Morphometry Trajectories as Predictors of Youth Persistent Distressing Psychotic-Like Experiences.Nature. Mental health · 2025Article
- Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 10 institutions in 3 countries.
Funding
Abstract
Progressive grey matter loss has been demonstrated among clinical high-risk (CHR) individuals who convert to psychosis, but it is unknown whether these changes occur prior to psychosis onset. Identifying illness-related neurobiological mechanisms that occur prior to conversion is essential for targeted early intervention. Among participants in the third wave of the North American Prodrome Longitudinal Study (NAPLS3), this report investigated if steeper cortical thinning was observable prior to psychosis onset among CHR individuals who ultimately converted (CHR-C) and assessed the shortest possible time interval in which rates of cortical thinning differ between CHR-C, CHR non-converters (CHR-NC), and health controls (HC). 338 CHR-NC, 42 CHR-C, and 62 HC participants (age 19.3±4.2, 44.8% female, 52.5% racial/ethnic minority) completed up to 5 MRI scans across 8 months. Accelerated thinning among CHR-C compared to CHR-NC and HC was observed in multiple prefrontal, temporal, and parietal cortical regions. CHR-NC also exhibited accelerated cortical thinning compared to HC in several of these areas. Greater percent decrease in cortical thickness was observed among CHR-C compared to other groups across 2.9±1.8 months, on average, in several cortical areas. ROC analyses discriminating CHR-C from CHR-NC by percent thickness change in a left hemisphere region of interest, scanner, age, age
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.